How Pharmas Can Help Private Health Insurers Achieve A Larger Role In China – McKinsey
This article was originally published in PharmAsia News
Burgeoning private health insurance in China has room for growth, and pharmaceutical companies can lend a hand. Roche has led the way, and there is plenty for other multinational drug and device manufacturers to gain, according to a recent McKinsey report.
You may also be interested in...
Podcast: Living In China's Coronavirus Lockdown; Novartis and England's 'Public Health' Alliance; Biogen's Moment of Truth Approaches
Several newly repurposed drugs, including a Bayer antimalarial, have shown potential benefits against the new coronavirus, promoting China to add several to its latest revised treatment guidelines.
Amid the ongoing spread of the coronavirus outbreak, China turns to novel and repurposed antiviral drugs but also courts traditional medicines to ease public fear over the largely unknown threat.